Latest Insider Transactions at Zentalis Pharmaceuticals, Inc. (ZNTL)
This section provides a real-time view of insider transactions for Zentalis Pharmaceuticals, Inc. (ZNTL). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Zentalis Pharmaceuticals, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Zentalis Pharmaceuticals, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 02
2025
|
Mark Lackner Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
4,411
-2.25%
|
$13,233
$3.12 P/Share
|
|
Nov 13
2024
|
Scott Dunseth Myers Director |
BUY
Grant, award, or other acquisition
|
Direct |
260,192
+50.0%
|
-
|
|
Oct 04
2024
|
Vincent Vultaggio Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
1,603
-4.52%
|
$4,809
$3.18 P/Share
|
|
Jun 21
2024
|
Enoch Kariuki Director |
BUY
Grant, award, or other acquisition
|
Direct |
41,581
+34.27%
|
-
|
|
Jun 21
2024
|
Jan Skvarka Director |
BUY
Grant, award, or other acquisition
|
Direct |
41,581
+31.71%
|
-
|
|
Jun 21
2024
|
David Michael Johnson Director |
BUY
Grant, award, or other acquisition
|
Direct |
48,429
+20.07%
|
-
|
|
May 31
2024
|
Cam Gallagher President, Interim CFO |
SELL
Open market or private sale
|
Direct |
9,597
-1.49%
|
$105,567
$11.98 P/Share
|
|
May 24
2024
|
Luke Nathaniel Walker Director |
BUY
Grant, award, or other acquisition
|
Direct |
72,481
+50.0%
|
-
|
|
May 09
2024
|
Diana Hausman Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,356
-0.89%
|
$40,272
$12.62 P/Share
|
|
Feb 12
2024
|
Cam Gallagher President, Interim CFO |
SELL
Open market or private sale
|
Direct |
1,173
-0.18%
|
$12,903
$11.44 P/Share
|
|
Feb 12
2024
|
Epperly Melissa B, Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,573
-0.57%
|
$28,303
$11.44 P/Share
|
|
Feb 02
2024
|
Andrea Paul Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
3,310
-2.16%
|
$36,410
$11.54 P/Share
|
|
Feb 02
2024
|
Mark Lackner Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,585
-0.8%
|
$17,435
$11.54 P/Share
|
|
Feb 02
2024
|
Epperly Melissa B, Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
8,669
-1.87%
|
$95,359
$11.54 P/Share
|
|
Feb 02
2024
|
Cam Gallagher President, Interim CFO |
SELL
Open market or private sale
|
Direct |
11,552
-1.76%
|
$127,072
$11.54 P/Share
|
|
Feb 01
2024
|
Andrea Paul Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
112,500
+42.33%
|
-
|
|
Feb 01
2024
|
Mark Lackner Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
141,000
+41.68%
|
-
|
|
Feb 01
2024
|
Diana Hausman Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
337,500
+47.22%
|
-
|
|
Feb 01
2024
|
Kimberly Blackwell Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
20,655
-4.09%
|
$227,205
$11.69 P/Share
|
|
Feb 01
2024
|
Kimberly Blackwell Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
250,000
+33.12%
|
-
|
|
Feb 01
2024
|
Epperly Melissa B, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
75,000
+13.95%
|
-
|
|
Feb 01
2024
|
Cam Gallagher President, Interim CFO |
BUY
Grant, award, or other acquisition
|
Direct |
192,500
+22.69%
|
-
|
|
Jan 02
2024
|
Mark Lackner Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+41.53%
|
-
|
|
Dec 20
2023
|
Kevin D. Bunker Chief Scientific Officer |
SELL
Bona fide gift
|
Direct |
24,158
-2.81%
|
-
|
|
Nov 13
2023
|
Kimberly Blackwell Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+1.92%
|
$50,000
$10.29 P/Share
|
|
Nov 10
2023
|
David Michael Johnson Director |
BUY
Open market or private purchase
|
Direct |
17,000
+10.53%
|
$153,000
$9.88 P/Share
|
|
Oct 04
2023
|
Carrie Brownstein Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
10,628
-4.63%
|
$201,932
$19.67 P/Share
|
|
Oct 04
2023
|
Epperly Melissa B, Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,482
-0.7%
|
$104,158
$19.67 P/Share
|
|
Oct 04
2023
|
Kevin D. Bunker Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
6,068
-0.35%
|
$115,292
$19.67 P/Share
|
|
Sep 11
2023
|
Jan Skvarka Director |
SELL
Open market or private sale
|
Direct |
5,000
-9.44%
|
$125,000
$25.05 P/Share
|
|
Jun 20
2023
|
Matrix Capital Management Company, LP > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
4,760,000
+25.43%
|
$104,720,000
$22.66 P/Share
|
|
Jun 16
2023
|
Jan Skvarka Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,364
+23.6%
|
-
|
|
Jun 16
2023
|
Enoch Kariuki Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,364
+30.0%
|
-
|
|
Jun 16
2023
|
David Michael Johnson Director |
BUY
Grant, award, or other acquisition
|
Direct |
19,059
+13.01%
|
-
|
|
May 31
2023
|
Cam Gallagher President, Interim CFO |
SELL
Open market or private sale
|
Direct |
27,768
-2.86%
|
$721,968
$26.3 P/Share
|
|
May 26
2023
|
Kevin D. Bunker Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
80,000
-84.21%
|
$2,400,000
$30.02 P/Share
|
|
May 08
2023
|
Diana Hausman Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
39,732
+50.0%
|
-
|
|
Mar 01
2023
|
Iris Roth Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
52,500
+50.0%
|
-
|
|
Feb 14
2023
|
Epperly Melissa B, Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,227
-1.32%
|
$99,313
$19.98 P/Share
|
|
Feb 14
2023
|
Kevin D. Bunker Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
6,500
-0.75%
|
$123,500
$19.98 P/Share
|
|
Feb 14
2023
|
Cam Gallagher President, Interim CFO |
SELL
Open market or private sale
|
Direct |
8,501
-1.7%
|
$161,519
$19.96 P/Share
|
|
Feb 13
2023
|
Epperly Melissa B, Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,624
-0.66%
|
$52,480
$20.42 P/Share
|
|
Feb 13
2023
|
Kevin D. Bunker Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,807
-0.43%
|
$76,140
$20.42 P/Share
|
|
Feb 13
2023
|
Cam Gallagher President, Interim CFO |
SELL
Open market or private sale
|
Direct |
3,332
-0.66%
|
$66,640
$20.42 P/Share
|
|
Feb 06
2023
|
Cam Gallagher President, Interim CFO |
SELL
Open market or private sale
|
Direct |
10,000
-0.98%
|
$220,000
$22.63 P/Share
|
|
Feb 01
2023
|
Carrie Brownstein Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
16,313
+12.3%
|
-
|
|
Feb 01
2023
|
Andrea Paul Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
40,783
+50.0%
|
-
|
|
Feb 01
2023
|
Epperly Melissa B, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
101,957
+20.32%
|
-
|
|
Feb 01
2023
|
Kimberly Blackwell Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
244,800
+49.49%
|
-
|
|
Feb 01
2023
|
Cam Gallagher President, Interim CFO |
BUY
Grant, award, or other acquisition
|
Direct |
161,092
+23.89%
|
-
|